clinicaltrialsarena5h
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...
clinicaltrialsarena6h
AAO 2024: Brepocitinib achieves treatment failure reductions in NEPTUNE
Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the ...
clinicaltrialsarena9h
Nexalin trials Halo neurostimulation device in traumatic brain injury
The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.
clinicaltrialsarena9h
IDWeek 2024: Prevention and treatment for HIV – clinical trials and policy challenges
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
clinicaltrialsarena10h
Otsuka’s sibeprenlimab shows promise in Phase III IgA nephropathy trial
Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...
clinicaltrialsarena20h
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint
Conducted across 34 sites in the US, the trial enrolled 301 adults with MDD. Credit: Suriyawut Suriya/Shutterstock. Alto Neuroscience (Alto) has reported that its Phase IIb clinical trial of ALTO-100 ...